Clinical Trial Update: 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

View source ↗

Summary

The clinical trial evaluating 68Ga DOTA-TATE PET/CT in somatostatin receptor–positive tumors is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor

Snippet

Sponsor: Andrei Iagaru | Conditions: Carcinoid Tumors, Islet Cell (Pancreatic NET) | Status: NO_LONGER_AVAILABLE